Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection

Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose

(2011) Amrita V. Kamath et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response

(2011) Z. Kang et al.   CLINICAL CANCER RESEARCH

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

(2011) Rong Deng et al.   mAbs

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

(2010) Nelson L. Jumbe et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

To scale or not to scale: the principles of dose extrapolation

(2009) Vijay Sharma et al.   BRITISH JOURNAL OF PHARMACOLOGY

Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

(2009) Jie Ling et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer

(2009) I. Zinonos et al.   MOLECULAR CANCER THERAPEUTICS

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

(2008) C Adams et al.   CELL DEATH AND DIFFERENTIATION

Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival

(2008) H. Jin et al.   CLINICAL CANCER RESEARCH

Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL ONCOLOGY